Sight Sciences to Report Second Quarter 2023 Financial Results on August 3, 2023
MENLO PARK, Calif., July 20, 2023 (GLOBE NEWSWIRE) -- Sight
Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on developing and commercializing innovative technology intended to transform care and improve patients' lives, today
announced it will report financial results for the second quarter ended June 30, 2023, after the market close on Thursday, August 3, 2023. The company’s management will discuss the results during a
conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
Investors interested in listening to the conference call may do so by accessing a live and archived webcast of the event at www.sightsciences.com, on the Investors page in the News & Events section. The webcast will be available for replay for at least 90 days after the event.
About Sight Sciences
Sight Sciences is an eyecare technology company focused on developing and commercializing innovative solutions intended to transform care and improve patients’ lives. Using minimally invasive or
non-invasive approaches to target the underlying causes of the world’s most prevalent eye diseases, Sight Sciences seeks to create more effective treatment paradigms that enhance patient care and
supplant conventional outdated approaches. The Company’s OMNI Surgical System is a minimally invasive glaucoma surgery (MIGS) technology indicated to reduce intraocular pressure in adult patients
with primary open-angle glaucoma (POAG), the world’s leading cause of irreversible blindness. The Company’s TearCare System technology is 510(k) cleared for the application of localized heat
therapy in adult patients with evaporative dry eye disease due to meibomian gland dysfunction (MGD) when used in conjunction with manual expression of the meibomian glands, enabling office-based
clearance of gland obstructions by physicians to address the leading cause of dry eye disease. The Company’s SION Surgical Instrument is a manually operated device used in ophthalmic surgical
procedures to excise trabecular meshwork.
For more information, visit http://www.sightsciences.com.
OMNI and TearCare are registered trademarks of Sight Sciences. SION is a trademark of Sight Sciences.
2023 Sight Sciences. All rights reserved.
Lesen Sie auch
Investor contact:
Philip Taylor
Gilmartin Group
415.937.5406
Investor.Relations@Sightsciences.com